West Pharma lifts 2026 guidance, adds dividend and credit facility
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
West Pharmaceutical Services posted higher Q3 2026 sales and net income and raised its full-year 2026 guidance, alongside a higher dividend and a new multi-currency credit facility. Analysts hold 16 Buy, 1 Hold and no Sell ratings, with a $416.40 target versus a $412.62 price, implying about 0.9% upside.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.